TENATHAN
LOE Approachingbethanidine sulfate
NDAORALTABLET
Approved
May 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 4h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TENATHAN (bethanidine sulfate) is an oral antihypertensive tablet approved in 1981 for blood pressure management. The mechanism of action and specific indications are not documented in available data. This is a legacy small-molecule product with limited modern clinical development.
LOE Approaching
Minimal commercial infrastructure likely remains; any team would be focused on managed decline and generic transition planning rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal active commercial investment. Career opportunities are primarily in managed care transition, generic partner coordination, and regulatory/compliance roles. This assignment reflects portfolio maintenance rather than growth opportunity.
Brand Manager (legacy portfolio)Medical Science Liaison (legacy support)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.